Can-Fite BioPharma Ltd.
CANF- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001536196
No open-market purchases or sales by Can-Fite BioPharma Ltd. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $149.1K in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Can-Fite BioPharma Ltd. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 16 | 16 | 0 |
| Shares | 1.54M | 596.6K | −942.0K (−61.2%) |
| Value | $952.6K | $78.3K | −$874.3K (−91.8%) |
New holders (3)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Advisor Group Holdings, Inc. | 36,000 | $7.20K | 0.00% |
| XTX Topco Ltd | 18,686 | $3.74K | 0.00% |
| Jane Street Group, LLC | 205,004 | – | – |
Sold out (3)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Sabby Management, LLC | 1,406,050 | $870.6K |
| BNP Paribas Arbitrage, SA | 16,585 | $10.3K |
| Captrust Financial Advisors | 11,375 | $7.04K |